Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 2
1990 2
1991 2
1993 3
1994 2
1995 5
1996 5
1997 3
1998 4
1999 2
2000 1
2001 4
2002 5
2003 1
2004 3
2006 4
2007 4
2008 9
2009 5
2010 4
2011 7
2012 12
2013 6
2014 3
2015 1
2016 1
2017 2
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Results by year
Filters applied: . Clear all
Page 1
Peptide-protein interactions: an overview.
Zvelebil MJ, Thornton JM. Zvelebil MJ, et al. Q Rev Biophys. 1993 Aug;26(3):333-63. doi: 10.1017/s0033583500002870. Q Rev Biophys. 1993. PMID: 8022970 Review. No abstract available.
Phosphoinositide 3-kinase signalling--which way to target?
Wymann MP, Zvelebil M, Laffargue M. Wymann MP, et al. Among authors: zvelebil m. Trends Pharmacol Sci. 2003 Jul;24(7):366-76. doi: 10.1016/S0165-6147(03)00163-9. Trends Pharmacol Sci. 2003. PMID: 12871670 Review. No abstract available.
Chemical development of intracellular protein heterodimerizers.
Erhart D, Zimmermann M, Jacques O, Wittwer MB, Ernst B, Constable E, Zvelebil M, Beaufils F, Wymann MP. Erhart D, et al. Among authors: zvelebil m. Chem Biol. 2013 Apr 18;20(4):549-57. doi: 10.1016/j.chembiol.2013.03.010. Chem Biol. 2013. PMID: 23601644
Flavopiridol Hoechst AG.
Zvelebil MJ. Zvelebil MJ. IDrugs. 1998 Jun;1(2):241-6. IDrugs. 1998. PMID: 18465538
Structural and functional diversity of phosphoinositide 3-kinases.
Zvelebil MJ, MacDougall L, Leevers S, Volinia S, Vanhaesebroeck B, Gout I, Panayotou G, Domin J, Stein R, Pages F, et al. Zvelebil MJ, et al. Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29;351(1336):217-23. doi: 10.1098/rstb.1996.0019. Philos Trans R Soc Lond B Biol Sci. 1996. PMID: 8650269 Review.
Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.
Rageot D, Bohnacker T, Melone A, Langlois JB, Borsari C, Hillmann P, Sele AM, Beaufils F, Zvelebil M, Hebeisen P, Löscher W, Burke J, Fabbro D, Wymann MP. Rageot D, et al. Among authors: zvelebil m. J Med Chem. 2018 Nov 21;61(22):10084-10105. doi: 10.1021/acs.jmedchem.8b01262. Epub 2018 Nov 14. J Med Chem. 2018. PMID: 30359003
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.
Bohnacker T, Prota AE, Beaufils F, Burke JE, Melone A, Inglis AJ, Rageot D, Sele AM, Cmiljanovic V, Cmiljanovic N, Bargsten K, Aher A, Akhmanova A, Díaz JF, Fabbro D, Zvelebil M, Williams RL, Steinmetz MO, Wymann MP. Bohnacker T, et al. Among authors: zvelebil m. Nat Commun. 2017 Mar 9;8:14683. doi: 10.1038/ncomms14683. Nat Commun. 2017. PMID: 28276440 Free PMC article.
Genomic characterisation of acral melanoma cell lines.
Furney SJ, Turajlic S, Fenwick K, Lambros MB, MacKay A, Ricken G, Mitsopoulos C, Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata H, Marais R. Furney SJ, et al. Among authors: zvelebil m. Pigment Cell Melanoma Res. 2012 Jul;25(4):488-92. doi: 10.1111/j.1755-148X.2012.01016.x. Pigment Cell Melanoma Res. 2012. PMID: 22578220
100 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page